Zimling Zarah Glad, Santoni-Rugiu Eric, Bech Cecilia, Sørensen Jens Benn
Department of Oncology, Finsen Centre/National University Hospital, Copenhagen, Denmark.
Department of Pathology, National University Hospital, Copenhagen, Denmark.
Anticancer Res. 2015 Dec;35(12):6731-8.
BACKGROUND/AIM: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. The present study aimed to further explore this finding in malignant pleural mesothelioma (MPM).
Seventy-one patients with MPM receiving first-line chemotherapy with cisplatin-vinorelbine (CiV group, n=54) or carboplatin-pemetrexed (CaP group, n=17) were included. Formalin-fixed paraffin-embedded tumor specimens were analyzed by immunohistochemistry (IHC) for RRM1 expression using an H-score.
In 66 patients eligible for IHC, the H-score was ≥upper quartile in 21 (RRM1-positive) and <upper quartile (RRM1-negative) in 45 cases. The long-term (2-year) survival rate for patients with RRM1-negative MPM in the CiV-treated group was significantly superior to that for patients with RRM1-positive MPM (47% versus 13%, p=0.002). No difference occurred in the CaP-treated group.
Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin-vinorelbine in MPM, supporting previous findings in NSCLC.
背景/目的：先前已有报道，核糖核苷酸还原酶亚基1（RRM1）可能对非小细胞肺癌（NSCLC）中长春瑞滨的疗效具有预测作用。本研究旨在进一步探讨这一发现是否适用于恶性胸膜间皮瘤（MPM）。
纳入71例接受一线化疗的MPM患者，其中顺铂-长春瑞滨组（CiV组，n = 54）或卡铂-培美曲塞组（CaP组，n = 17）。采用免疫组织化学（IHC）方法，利用H评分对福尔马林固定石蜡包埋的肿瘤标本进行RRM1表达分析。
在66例符合IHC检测条件的患者中，H评分≥上四分位数的有21例（RRM1阳性），＜上四分位数的有45例（RRM1阴性）。CiV治疗组中RRM1阴性的MPM患者的长期（2年）生存率显著高于RRM1阳性的MPM患者（47%对13%，p = 0.002）。CaP治疗组未观察到差异。
我们的研究结果表明，RRM1可能在预测顺铂-长春瑞滨对MPM的疗效中发挥作用，这支持了先前在NSCLC中的研究结果。
